Endogenous CRISPR ‐Based Removal of Tetracycline Resistance in Bifidobacterium animalis subsp. lactis Through a Safe‐by‐Design Approach
Microbial Biotechnology · 2026
DOI: 10.1111/1751-7915.70443 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Biotechnology, 2026. Verfasst von Marianna Bozzetti und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department for Sustainable Food Process-DiSTAS, Università Cattolica del Sacro Cuore, Cremona, Italy. Hauptthemen laut MEDLINE: Tetracycline Resistance, Bifidobacterium animalis, CRISPR-Cas Systems, Gene Editing. Die Arbeit nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Recovery and Resilence Plan Next generation EU, OnFoods, Fondazione Romeo ed Enrica Invernizzi.
Abstract (Originalsprache)
Bifidobacterium animalis subsp. lactis is widely used as a probiotic; however, the presence of the tetracycline resistance gene tetW raises safety and regulatory concerns due to its potential mobility within the gut microbiome. Here, we applied a Safe‐by‐Design strategy using the endogenous CRISPR‐Cas system of B. animalis subsp. lactis BLC01 to inactivate tetW through the introduction of premature stop codons. Whole‐genome sequencing confirmed the intended editing and excluded relevant off‐target effects. tetW inactivation markedly reduced the tetracycline minimum inhibitory concentration, restoring susceptibility below the tetracycline cut‐off value for bifidobacteria (8 μg/mL). Comparative phenotypic analyses demonstrated that the edited strain (BLC01‐2F3G10) retained key probiotic traits, including tolerance to acid, bile, and osmotic stress, exopolysaccharide production, aggregation capacity, survival during simulated gastrointestinal digestion and adhesion to intestinal epithelial cells. Importantly, no reversion to tetracycline resistance was observed after prolonged exposure to sub‐inhibitory minimal selective antimicrobial concentration, indicating genetic stability of the edited phenotype. Collectively, these findings demonstrate that endogenous CRISPR‐based genome editing can be leveraged to selectively remove antimicrobial resistance determinants from probiotic strains while preserving functionality, supporting the development of next‐generation probiotics with an improved safety profile and reduced potential for antimicrobial resistance dissemination in the human gut.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department for Sustainable Food Process-DiSTAS, Università Cattolica del Sacro Cuore, Cremona, Italy.
- Sacco srl, Cadorago, Como, Italy.
- Institute of Advanced Science for Agriculture, Jolanda di Savoia (FE), Italy.
ORCID-Profile: Marianna Bozzetti, Matteo Raneri, Claudia Cortimiglia, Giovanni Milani, Federica Volontè, Franco Lucchini, Daniela Bassi, Pier Sandro Cocconcelli
Förderung
- National Recovery and Resilence Plan Next generation EU, OnFoods
- Fondazione Romeo ed Enrica Invernizzi
Zitieren
APA
Bozzetti, M., Raneri, M., Cortimiglia, C., Milani, G., Volontè, F., Lucchini, F., Bassi, D., & Cocconcelli, P. S. (2026). Endogenous CRISPR ‐Based Removal of Tetracycline Resistance in Bifidobacterium animalis subsp. lactis Through a Safe‐by‐Design Approach. Microbial Biotechnology. https://doi.org/10.1111/1751-7915.70443
Vancouver
Bozzetti M, Raneri M, Cortimiglia C, Milani G, Volontè F, Lucchini F, et al. Endogenous CRISPR ‐Based Removal of Tetracycline Resistance in Bifidobacterium animalis subsp. lactis Through a Safe‐by‐Design Approach. Microbial Biotechnology. 2026. doi:10.1111/1751-7915.70443
BibTeX
@article{Bozzetti2026,
author = {Bozzetti, Marianna and Raneri, Matteo and Cortimiglia, Claudia and Milani, Giovanni and Volontè, Federica and Lucchini, Franco and Bassi, Daniela and Cocconcelli, Pier Sandro},
title = {Endogenous CRISPR ‐Based Removal of Tetracycline Resistance in Bifidobacterium animalis subsp. lactis Through a Safe‐by‐Design Approach},
journal = {Microbial Biotechnology},
year = {2026},
doi = {10.1111/1751-7915.70443}
}
EUVIMED